Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072196 · ClinicalTrials.gov registry record
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 3,017
- Enrollment target
NCT06072196 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 3,017 participants.
The verdict
NCT06072196 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 3,017 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about how long novel hormonal therapies are taken by men to treat mCSPC. Novel hormonal therapies in this study include study medicines abiraterone, apalutamide, and enzalutamide. Prostate cancer is one of the most common cancers in men. The prostate is a gland in the male body that helps make semen. Metastatic cancer is a cancer that has spread to other parts of the body. Castration-sensitive prostate cancer means the cancer is being controlled by keeping the testosterone levels as low as would be expected if the testicles were removed by surgery. This is a real-world study, not a clinical trial. This means that researchers will look at what happens when men receive the treatments prescribed by their own doctor as part of their usual healthcare treatment. In this study, researchers will use insurance claim information from Medicare claims data. The study will include patients' information from the database for men who: * Were identified to have mCSPC. * Started treatment with novel hormonal therapy (index date) for mCSPC. * Were 65 years of age or older one year before index date. Men in this study will be taking novel hormonal therapy for treatment of their mCSPC. We will describe how long men take novel hormonal therapy. This study will use patient information from insurance claims. It will take information one year before start of novel hormonal treatment until the end of insurance period or until information is available.
Interventions
- DRUG Novel hormonal therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,017 participants |
| Start Date | 2023-10-04 |
| Est. Completion | 2024-12-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06072196
The ClinicalTrials.gov registry entry for NCT06072196 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,017 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Novel hormonal therapy is the first listed.
NCT06072196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06072196 about?
NCT06072196 is a clinical study titled "A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)". The purpose of this study is to learn about how long novel hormonal therapies are taken by men to treat mCSPC. Novel hormonal therapies in this study include study medicines abiraterone, apalutamide, and enzalutamide. Prostate cancer is one of the most common cancers in men. The prostate is a gland...
What is the current status of trial NCT06072196?
This trial is currently completed. The enrollment target is 3,017 participants. The study started on 2023-10-04. Estimated completion is 2024-12-18.
What interventions are being tested in trial NCT06072196?
The interventions under investigation include: Novel hormonal therapy (DRUG).
Who is sponsoring clinical trial NCT06072196?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.